We value innovation, creativity and individual initiative.

What we do

Discovering New Approaches to Therapy in the Field of Medicine

About Us

We are a publicly traded biotechnology company focused on the development and commercialization of Phorbol 12-myristate 13-acetate (PMA) internal i.d. RP-323, a focused immunotherapy and stem cell activator for treating neurological diseases (CNS).

Read More

Science

HypGen Inc is developing a proprietary ‘platform’ technology, a differentiation agent phorbol 12-myristate 13-acetate (PMA) internally called RP-323

Read More

Research

A phase I safety study has been completed and the company is now prepared to enter into phase I/II clinical study in Parkinson’s disease in collaboration with a major University Hospital in Atlanta Georgia.

Read More

Patient

It is believed that between 7 to 10 million people worldwide are affected and that 60,000 new cases are diagnosed annually in the United States alone.

Read More

RECENT NEWS

HypGen, Inc. is committed to good corporate citizenship. Our policy is to conduct our business affairs honestly and ethically.